跳至主要内容
临床试验/NCT07163000
NCT07163000进行中(未招募)不适用

Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT)

Weill Cornell Medical College in Qatar1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2025年5月11日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
150
试验地点
1
主要终点
Validation of the ACT tool

研究概览

简要总结

This study is looking at people with diabetes (type 1 and type 2 diabetes) to see how well a short questionnaire, called the ACT, can identify nerve damage in the feet and legs (also known as peripheral neuropathy). The investigators will compare the ACT questionnaire to other commonly used tools (the DN4 and Michigan Neuropathy Screening Instrument) and to an eye-test that detects small nerve fibers in the eye (called corneal confocal microscopy, or CCM).

The main goal is to find out if the ACT questionnaire is accurate in detecting nerve damage and painful nerve damage caused by diabetes.

The investigators will also look at whether changes in blood sugar levels, measured with a continuous glucose monitor (Freestyle Libre 3 and iCan), are linked to nerve pain and small nerve fiber damage.

详细描述

This a cross-sectional cohort study in patients with diabetes with the aim of assessing the validity and diagnostic accuracy of the ACT questionnaire in identifying peripheral neuropathy (PN) in patients with diabetes and explore underlying mechanisms for nerve damage. The primary endpoint is to validate the ACT tool in identifying diabetic painful neuropathy against the DN4 questionnaire, Michigan Neuropathy Screening Instrument (MNSI) and in relation to underlying small nerve fibre damage (CCM). And the secondary endpoints include the investigation of the association between glycemic indices using continuous glucose monitoring (CGM- Freestyle Libre 3 and iCan) with neuropathic pain (ACT/DN4/MNSI) and small nerve fibre damage (CCM).

Participants will attend 3 visits and the following will be assessed:

  • Visit 1(baseline): Consent, screening, CCM, ACT, MNSI, DN4, CGM (Freestyle Libre 3).
  • Visit 2 (14-days follow-up): CGM (freestyle Libre 3), ACT, MNSI, DN4
  • Visit 3 (between 1-6 months): CGM (iCan)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with diabetes (T1DM and T2DM)
  • Able to provide consent.
  • Able to sit still for corneal confocal microscopy

排除标准

  • Failure to provide informed consent
  • Participants with a history of ocular trauma or previous ocular surgery in the preceding 6 months, are allergic to oxybuprocaine or local anesthetics or unable to cooperate by holding still or placing their chin on an optical device
  • Other causes of peripheral neuropathy: vitamin B12 deficiency; hypothyroidism; myeloma.
  • Cognitively impaired participants
  • Pregnant women
  • Nursing women

结局指标

主要结局

Validation of the ACT tool

时间窗: Baseline (Day 1) and then 14 days after visit 1

Identification of number of participants with diabetic peripheral neuropathy as assessed by the ACT tool.

次要结局

未报告次要终点

研究者

发起方
Weill Cornell Medical College in Qatar
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Earlier Diagnosis of Peripheral Neuropathy Using A... | 临床试验